Recruiting PHASE4 INTERVENTIONAL 2-arm NCT05242315

Extended-Release Tacrolimus Following Liver Transplantation

Feasibility, Efficacy And Safety Of De Novo Extended-Release Tacrolimus Following Liver Transplantation

Sponsor: University of Alberta

Conditions Cardiovascular Diseases Immunosuppressant Adverse Reaction Liver Transplant; Complications Metabolic Syndrome Renal Insufficiency

Interventions Envarsus Oral Product Prograf (SOC)

Updated 11 times since 2022 Last updated: Aug 19, 2025 Started: May 15, 2022 Primary completion: Dec 15, 2026 Completion: Feb 15, 2034

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Cardiovascular Diseases and Immunosuppressant Adverse Reaction, this trial is actively recruiting participants. The trial is conducted by University of Alberta and has accumulated 11 data snapshots since 2022. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE4
Apr 2025 — Sep 2025 [monthly]

Recruiting PHASE4
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE4

▶ Show 6 earlier versions

Sep 2023 — Apr 2024 [monthly]

Recruiting PHASE4
Apr 2023 — Sep 2023 [monthly]

Recruiting PHASE4
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE4

Status: Suspended → Recruiting
Sep 2022 — Mar 2023 [monthly]

Suspended PHASE4

Status: Not Yet Recruiting → Suspended
May 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE4
Mar 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Alberta

Data source: University of Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada